NAPLES, Fla., June 3, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer patients, and MagicMed Industries (“MagicMed”),…
With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules Enveric aims to move into the clinic with…
NAPLES, Fla., May 18, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid (CBD) medicines to improve quality of life for cancer patients,…
Cedars-Sinai Veteran Physician Joins Four Additional Clinical, Oncology and Cannabinoid Experts to Guide the Company’s Research and Scientific Programs NAPLES, Fla., May 12, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a…
NAPLES, FL / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today…
NAPLES, Fla., April 12, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that…
Strengthened balance sheet during the first quarter of 2021 with the closing of two direct offerings totaling $22.8 million in gross proceeds and $3.3 million from the exercise of warrants…
– Dr. Douglas Lind brings over 30 years of healthcare and capital markets experience to the board – NEW YORK, March 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first…
NAPLES, Fla., March 15, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David…
– License has the Potential to Expand Enveric’s Planned Capabilities to Address Cancer Treatment Side Effects – – Innovative Conjugation Platform Aims to Provide Superior Therapeutic Outcomes for Patients by…